Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cevipabulin (TTI-237) is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 50.00 | |
5 mg | In stock | $ 90.00 | |
10 mg | In stock | $ 139.00 | |
25 mg | In stock | $ 297.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 107.00 |
Description | Cevipabulin (TTI-237) is a microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin (IC50: 18-40 nM in the human tumor cell line). |
Targets&IC50 | Microtubule (human tumor cells):18-40 nM |
In vitro | Cevipabulin (0-50 nM, 72 hours) shows good activity (IC50s: 18~40 nM) on cell lines from ovarian, breast, prostate, and cervical tumors. Cevipabulin at low concentrations (20-40 nM) produces sub-G1 nuclei and, at concentrations above 50 nM, it causes a strong G2-M block [1]. |
In vivo | In mice, Cevipabulin ( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles; i.v. and p.o.) is active against human tumor xenografts and showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg [1]. |
Synonyms | TTI-237 |
Molecular Weight | 464.82 |
Formula | C18H18ClF5N6O |
CAS No. | 849550-05-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 15.3 mg/mL (32.9 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cevipabulin 849550-05-6 Cytoskeletal Signaling Microtubule Associated TTI 237 TTI-237 TTI237 inhibitor inhibit